Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition.
Priem B, van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, Klein ED, Oosterwijk RS, Meerwaldt AE, Munitz J, Prévot G, Vera Verschuur A, Nauta SA, van Leeuwen EM, Fisher EL, de Jong KAM, Zhao Y, Toner YC, Soultanidis G, Calcagno C, Bomans PHH, Friedrich H, Sommerdijk N, Reiner T, Duivenvoorden R, Zupančič E, Di Martino JS, Kluza E, Rashidian M, Ploegh HL, Dijkhuizen RM, Hak S, Pérez-Medina C, Bravo-Cordero JJ, de Winther MPJ, Joosten LAB, van Elsas A, Fayad ZA, Rialdi A, Torre D, Guccione E, Ochando J, Netea MG, Griffioen AW, Mulder WJM. Priem B, et al. Among authors: van elsas a. Cell. 2020 Oct 29;183(3):786-801.e19. doi: 10.1016/j.cell.2020.09.059. Cell. 2020. PMID: 33125893 Free PMC article.
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.
Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM. Sivick KE, et al. Among authors: van elsas a. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047. Cell Rep. 2018. PMID: 30540940 Free article.
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E, Paradé M, Lutje Hulsik D, Spijkers S, Janssen W, Rens J, Reinieren-Beeren I, van den Tillaart G, van Duijnhoven S, Driessen L, Habraken M, van Zandvoort P, Kreijtz J, Vink P, van Elsas A, van Eenennaam H. Voets E, et al. Among authors: van duijnhoven s, van eenennaam h, van zandvoort p, van elsas a, van den tillaart g. J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0. J Immunother Cancer. 2019. PMID: 31801627 Free PMC article.
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.
Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, Liu L, Kang SP, Fayadat-Dilman L, Hsieh M, Andrews CL, Ayanoglu G, Cullen C, Malefyt RW, Kastelein RA, Saux SL, Lee J, Li S, Malashock D, Sadekova S, Soder G, van Eenennaam H, Willingham A, Yu Y, Streuli M, Carven GJ, van Elsas A. Hutchins B, et al. Among authors: van eenennaam h, van elsas a. Mol Cancer Ther. 2020 Jun;19(6):1298-1307. doi: 10.1158/1535-7163.MCT-19-0774. Epub 2020 Mar 30. Mol Cancer Ther. 2020. PMID: 32229606
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. Huang S, et al. Among authors: van duijnhoven smj, van elsas a. J Cancer Res Clin Oncol. 2020 Dec;146(12):3111-3122. doi: 10.1007/s00432-020-03404-6. Epub 2020 Sep 28. J Cancer Res Clin Oncol. 2020. PMID: 32989604 Free PMC article. Review.
Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.
Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Sullivan TJ, et al. Among authors: van elsas a, van amelsfort j. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2587-92. doi: 10.1073/pnas.051632398. Epub 2001 Feb 20. Proc Natl Acad Sci U S A. 2001. PMID: 11226283 Free PMC article.
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L, Fischmann TO, Wong J, Mauze S, Guadagnoli M, Bąbała N, Wagenaars J, Juan V, Rosen D, Prosise W, Habraken M, Lodewijks I, Gu D, Stammen-Vogelzangs J, Yu Y, Baker J, Lutje Hulsik D, Driessen-Engels L, Malashock D, Kreijtz J, Bertens A, de Vries E, Bovens A, Bramer A, Zhang Y, Wnek R, Troth S, Chartash E, Dobrenkov K, Sadekova S, van Elsas A, Cheung JK, Fayadat-Dilman L, Borst J, Beebe AM, Van Eenennaam H. Guelen L, et al. Among authors: van elsas a. J Immunother Cancer. 2022 Sep;10(9):e005049. doi: 10.1136/jitc-2022-005049. J Immunother Cancer. 2022. PMID: 36100308 Free PMC article.
50 results